IFNA1 and dermatomyositis: Except for JAK inhibitors, sifalimumab, one of the anti-IFNα monoclonal antibodies, has shown a target neutralization of a type I IFN signature in the blood of DM and PM patients in a phase Ib clinical trial (81).